Expression Of MTOR And VEGF In Gastric Carcinoma And Correlation With Prognosis

Objective: To detect the relationship between the expression of mTOR and VEGF in gastric carcinoma and to investigate its influence on prognosis.Methods: A total of 1072 patients with gastric endothelial carcinoma who underwent curative surgery from 2001 to 2005 were followed up by telephone in this study. Tissue microarrays containing 1072 cases of tumor specimens were constructed. mTOR , p-mTOR and VEGF expression were investigated by immunohistochemical studies. The Kaplan-Meier method was used to estimate survival rates, and the log-rank and the Wilcoxon rank sum tests were used to assess survival differences between groups. The Cox proportional hazards model for multivariate survival analysis was used to assess predictors related to survival.Results: Clinical follow-up were available for 669 patients. The overall expression rates of mTOR, p-mTOR and VEGF in cancer were 50.8%, 46.5% and 59.4%, respectively. Over-expression of mTOR, p-mTOR and VEGF protein were associated with many clinicopathological factors and prognosis.Conclusion: It is very essential to follow up the patients after surveys for survival rate no matter the retrospective or prospective research. Tissue microarrays containing 1072 patients for the research of gastric cancer were constructed successfully. mTOR/VEGF signaling is frequently activated in human gastric cancer. mTOR, p-mTOR and VEGF were associated with clinicopathological factors and play a very important role in prognosis. The median survival period of negative expression in these protein are longer than the positive. mTOR, p-mTOR and VEGF may be regarded as the potential molecular targets for therapy.